A Phase 3 interventional study of Gatifloxacin 0.5% eye drops and placebo eye drops in Bacterial Conjunctivitis, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.
This study's enrollment of 859 is above the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.
Browse Conjunctivitis, Bacterial studies →Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gatifloxacin 0.5% Eye Drops
Drug: Gatifloxacin 0.5% eye drops
Placebo Eye Drops
Drug: placebo eye drops
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
Time frame: 6 Days
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
Time frame: Day 6
Percentage of Patients With Microbiological Cure Up to Day 6
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture).
Time frame: 6 Days
Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6
Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.
Time frame: 6 Days
Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6
Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis.
Time frame: 6 Days
| Milestone | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Started | 430 | 429 |
| Completed | 402 | 398 |
| Not completed | 28 | 31 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
| Percentage of Patients | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 | 59.6 | 46.7 |
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture).
| Percentage of Patients | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Percentage of Patients With Microbiological Cure Up to Day 6 | 92.2 | 80.2 |
Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.
| Percentage of Patients | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6 | 97.0 | 92.2 |
Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis.
| Percentage of Patients | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6 | 92.8 | 88.6 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
| Percentage of Patients | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 | 51.8 | 41.3 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gatifloxacin 0.5% Eye Drops | — | 2/429 (0.5%) | 19/429 (4.4%) |
| Placebo Eye Drops | — | 0/427 (0%) | 26/427 (6.1%) |
| Event | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| AnxietyPsychiatric disorders | 1/429 | 0/427 |
| DepressionPsychiatric disorders | 1/429 | 0/427 |
| Event | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops |
|---|---|---|
| Conjunctivitis bacterialInfections and infestations | 5/429 | 19/427 |
| Eye IrritationEye disorders | 14/429 | 7/427 |
| Age, Customized(participants) | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops | Total |
|---|---|---|---|
| 1-18 years | 66 | 74 | 140 |
| 19-65 years | 316 | 313 | 629 |
| >65 years | 48 | 42 | 90 |
| Sex: Female, Male(Participants) | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops | Total |
|---|---|---|---|
| Female | 183 | 156 | 339 |
| Male | 247 | 273 | 520 |
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gatifloxacin